Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other financing activities (2016 - 2024)

Tg Therapeutics has reported Other financing activities over the past 4 years, most recently at $31000.0 for Q4 2024.

  • Quarterly results put Other financing activities at $31000.0 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2025 was $889000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $889000.0, up 611.2%.
  • Other financing activities for Q4 2024 was $31000.0 at Tg Therapeutics, down from $858000.0 in the prior quarter.
  • Over the last five years, Other financing activities for TGTX hit a ceiling of $858000.0 in Q3 2024 and a floor of $31000.0 in Q4 2024.